NASDAQ$VRNA
Verona Pharma plc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Verona Pharma reported strong Q4 2024 revenue growth, driven by the successful launch of Ohtuvayre.
Verona Pharma reported Q4 2024 revenue of $36.6 million, primarily from the commercial launch of Ohtuvayre, its novel inhaled COPD therapy. The company posted a net loss of $33.8 million due to increased R&D and SG&A expenses related to commercialization and ongoing clinical trials. Cash and cash equivalents increased to $399.8 million, strengthening Verona’s financial position as it advances its pipeline programs.
- Q4 2024 revenue reached $36.6 million, driven by strong Ohtuvayre sales.
- Net loss increased to $33.8 million due to commercialization and R&D investments.
- Cash reserves grew to $399.8 million, supporting future growth initiatives.
- Regulatory approvals and Phase 2 clinical trials remain key priorities for 2025.
Headline financials
Revenue & EPS history
Verona Pharma · Revenue · Quarterly
$36.6M
Forward guidance
Verona Pharma plans to continue commercializing Ohtuvayre while advancing regulatory approvals and clinical trials in 2025.
Tailwinds
- Ohtuvayre sales momentum continues into early 2025 with growing prescriber adoption.
- Plans for regulatory submissions in the EU and UK for Ohtuvayre approval.
- Ongoing Phase 2 trials in bronchiectasis and fixed-dose combination therapy progressing.
- Nuance Pharma’s Phase 3 trial results in China expected mid-2025.
- Strong cash position allows for continued R&D investment and commercialization efforts.
Headwinds
- Higher SG&A and R&D expenses are expected to continue impacting profitability.
- Increased competition in the COPD market may challenge market penetration.
- Potential regulatory delays could impact international expansion plans.
- R&D expenditures will remain elevated as additional trials progress.
- Uncertain economic conditions may affect healthcare spending trends.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q4 2024
+3.3%
Avg return
Earnings day
+7.2%
Avg return
5 days after
+5.6%
Avg return
30 days after
48%
12 / 25 earnings
Positive
+56.8%
Q2 2022
Best reaction
-14.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | -0.0% | -0.1% | +0.9% | |
| Q1 2025 | +6.4% | +5.6% | +12.5% | |
| Q4 2024 | +5.7% | +6.4% | +1.5% | |
| Q3 2024 | +9.7% | +10.2% | +14.0% | |
| Q2 2024 | +15.8% | +36.5% | +35.1% | |
| Q1 2024 | -0.2% | -6.8% | -18.4% | |
| Q4 2023 | +5.4% | -1.1% | -6.4% | |
| Q3 2023 | +7.6% | — | — | |
| Q2 2023 | -3.4% | — | — | |
| Q1 2023 | +7.1% | — | — | |
| Q4 2022 | -8.5% | — | — | |
| Q3 2022 | -5.8% | — | — | |
| Q2 2022 | +56.8% | — | — | |
| Q1 2022 | +3.8% | — | — | |
| Q4 2021 | -1.1% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q2 2021 | +3.9% | — | — | |
| Q1 2021 | -4.4% | — | — | |
| Q4 2020 | -0.1% | — | — | |
| Q2 2020 | +10.3% | — | — | |
| Q4 2019 | -14.7% | — | — | |
| Q4 2018 | -3.3% | — | — | |
| Q3 2018 | +2.1% | — | — | |
| Q4 2017 | -3.5% | — | — | |
| Q3 2017 | -4.2% | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro